Eltrombopag-Induced Acute Liver Failure in a Pediatric Patient: A Pharmacokinetic and Pharmacogenetic Analysis.
Ther Drug Monit
; 40(4): 386-388, 2018 08.
Article
em En
| MEDLINE
| ID: mdl-29683873
ABSTRACT
Eltrombopag is an oral thrombopoietin receptor agonist approved for the treatment of patients with chronic idiopathic thrombocytopenic purpura (ITP), who are more than 1 year old, and show poor response to first-line therapy. ITP is a hematological disorder characterized by isolated thrombocytopenia in the absence of secondary causes or disorders. Eltrombopag is generally well tolerated in the pediatric population; therefore, therapeutic drug monitoring (TDM) is not usually performed in clinical practice.We presented the case study of a 3-year-old girl with chronic ITP. She arrived in the pediatric intensive care unit with acute liver failure due to eltrombopag toxicity despite taking the standard drug dosage. A very high eltrombopag plasma concentration, indicating drug toxicity, was found through TDM. The patient also carried the allelic variations that are involved in drug metabolism [CYP2C8 and UDP glucuronosyltransferase (UGT) 1A1 (UGT1A1)] and drug cellular transportation [ABCG2 (ATP-binding cassette G2)]. This observation highlights the importance of using TDM and pharmacogenetic approaches to manage patients' unusual complications associated with standard pharmacological treatment regimens.
Texto completo:
1
Coleções:
01-internacional
Temas:
Geral
Base de dados:
MEDLINE
Assunto principal:
Pirazóis
/
Benzoatos
/
Glucuronosiltransferase
/
Falência Hepática Aguda
/
Citocromo P-450 CYP2C8
/
Membro 2 da Subfamília G de Transportadores de Cassetes de Ligação de ATP
/
Hidrazinas
/
Proteínas de Neoplasias
Limite:
Child, preschool
/
Female
/
Humans
Idioma:
En
Revista:
Ther Drug Monit
Ano de publicação:
2018
Tipo de documento:
Article